dacarbazine - CISMeF

Preferred Label : dacarbazine;

MeSH definition : An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564);

MeSH synonym : imidazole carboxamide, dimethyl; dic; dimethyl triazeno imidazole carboxamide; 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide; dimethyl imidazole carboxamide; decarbazine; icdt; carboxamide, dimethyl imidazole; dtic;

MeSH hyponym : deticene; NSC-45388; DTIC-Dome; biocarbazine; NSC 45388; NSC45388; DTIC Dome; DTICDome;

MeSH CAS label : 1H-Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-;

MeSH Related Number : 4342-03-4 (Dacarbazine);

Registry Number MeSH : 4342-03-4;

Wikipedia link : https://en.wikipedia.org/wiki/Dacarbazine;

Codes EINECS : 224-396-1;

Is substance : O;

UNII : 7GR28W0FJI;

InChIKey : FDKXTQMXEQVLRF-ZHACJKMWSA-N;

Details

Origin ID

D003606;

UMLS CUI

C0010927;

ATC code(s)
- dacarbazine [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- DIC [WHO-ART Included Term]
- DIC [MedDRA LLT]
- Dacarbazine [ICD-11 Extension code]
- dic [TUV Concept]
- dic [TUV Concept]
CISMeF manual mappings
- Dacarbazine poisoning (disorder) [SNOMED CT concept]
- dacarbazine [Substance BNPC]
Currated CISMeF NLP mapping
- Dacarbazine [NCIt concept]
- Dacarbazine (substance) [SNOMED CT concept]
- dacarbazine [SNOMED Notion]
False automatic mappings
- Dicentric Chromosome [NCIt concept]
- Disseminated Intravascular Coagulation [NCIt concept]
- Disseminated intravascular coagulation [ICD-11 Category]
- Disseminated intravascular coagulation [MedDRA Preferred Term]
- Solute carrier family 25 (mitochondrial carrier), member 10 [OMIM gene]
- disseminated intravascular coagulation [DO Concept]
Pharmacological action(s)
- antineoplastic agents, alkylating [MeSH Descriptor]
Record concept(s)
- DTIC-Dome [MeSH concept]
- NSC-45388 [MeSH concept]
- biocarbazine [MeSH concept]
- dacarbazine [MeSH concept]
- deticene [MeSH concept]
Related MeSH Supplementary Concept(s)
- 1,4-dihydro-7,8-dimethyl-6H-pyrimido(1,2-b)-1,2,4,5-tetrazin-6-one [MeSH Supplementary Concept]
- 5-(3,3-dimethyl-1-triazeno)-1-methylimidazole-4-carboxamide [MeSH Supplementary Concept]
- 5-(3-(2-chloroethyl)triazen-1-yl)imidazole-4-carboxamide [MeSH Supplementary Concept]
- 5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide [MeSH Supplementary Concept]
- 5-(3-methyl-1-triazeno)imidazole-4-carboxamide [MeSH Supplementary Concept]
- ABDIC protocol [MeSH Supplementary Concept]
- ABOD protocol [MeSH Supplementary Concept]
- ABV-ADV protocol [MeSH Supplementary Concept]
- ABVD protocol [MeSH Supplementary Concept]
- ABVDP protocol [MeSH Supplementary Concept]
- ADIC protocol [MeSH Supplementary Concept]
- B-DOPA protocol [MeSH Supplementary Concept]
- BELD protocol [MeSH Supplementary Concept]
- BOLD protocol [MeSH Supplementary Concept]
- CADOM protocol [MeSH Supplementary Concept]
- COPP-ABVD protocol [MeSH Supplementary Concept]
- CVD protocol [MeSH Supplementary Concept]
- CYOMAD protocol [MeSH Supplementary Concept]
- CYVADIC protocol [MeSH Supplementary Concept]
- CYVEDIC protocol [MeSH Supplementary Concept]
- CyADIC regimen [MeSH Supplementary Concept]
- DAV protocol [MeSH Supplementary Concept]
- DBCT protocol [MeSH Supplementary Concept]
- DBPT protocol [MeSH Supplementary Concept]
- DBPT regimen [MeSH Supplementary Concept]
- DECAV protocol [MeSH Supplementary Concept]
- DMAP protocol [MeSH Supplementary Concept]
- DTIC-LVFU2 protocol [MeSH Supplementary Concept]
- DVP protocol [MeSH Supplementary Concept]
- EBVD protocol [MeSH Supplementary Concept]
- EID protocol [MeSH Supplementary Concept]
- FDE protocol [MeSH Supplementary Concept]
- FIVB+P protocol [MeSH Supplementary Concept]
- IVADIC regimen [MeSH Supplementary Concept]
- MADDOC protocol [MeSH Supplementary Concept]
- MAID protocol [MeSH Supplementary Concept]
- NEO212 [MeSH Supplementary Concept]
- PADIC protocol [MeSH Supplementary Concept]
- VABCD protocol [MeSH Supplementary Concept]
- VACAD protocol [MeSH Supplementary Concept]
- VADIC protocol [MeSH Supplementary Concept]
- VDD protocol [MeSH Supplementary Concept]
- ethazolastone [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Dacarbazine [NCIt concept]
- Dacarbazine (substance) [SNOMED CT concept]
- Product containing dacarbazine (medicinal product) [SNOMED CT concept]
- dacarbazine [ATC Code]
- dacarbazine [Substance BNPC]
- dacarbazine [SNOMED Notion]
Validated automatic mappings to BTNT
- dacarbazine [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients